Compare · GLP-1 agonist
Liraglutide vs Tirzepatide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Liraglutide | Tirzepatide | |
|---|---|---|
| Evidence | 10/10 | 10/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A once-daily GLP-1 drug with large RCT support for glucose control, weight loss, and lower cardiovascular risk in high-risk type 2 diabetes. | A dual GIP/GLP-1 receptor agonist with strong RCT evidence for type 2 diabetes, weight loss, and sleep apnea; GI side effects are common. |
| Full profile → | Full profile → |
Liraglutide
Liraglutide is one of the most thoroughly studied metabolic drugs of the last fifteen years, and it's the direct predecessor to semaglutide. Its two approved uses rest on large, repeated, double-blind randomized trials (carefully controlled studies where neither patients nor doctors know who got…
Tirzepatide
Tirzepatide is a once-a-week injectable peptide. You may know it by its brand names: Mounjaro (for type 2 diabetes) and Zepbound (for weight management and sleep apnea). Most of the compounds we write about here have thin evidence behind them. This one is different: it has been tested in large,…